Salarius Pharmaceuticals, Inc.
SLRX
$0.698
-$0.0348-4.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -66.01% | 60.21% | 63.26% | 67.88% | 86.16% |
| Total Depreciation and Amortization | 0.00% | -80.36% | -35.29% | -35.29% | -35.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -40.28% | -75.28% | -31.01% | -61.88% | -34.86% |
| Change in Net Operating Assets | 193.49% | 71.33% | 140.04% | -85.62% | -146.96% |
| Cash from Operations | 50.87% | 63.81% | 75.72% | 57.28% | 67.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 36.84% | 37.31% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -98.67% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 36.84% | 745.85% | -100.42% | -151.32% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.46% | 100.28% | -148.52% | 46.11% | 64.35% |